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A mixed methods study of HIV-related
services in buprenorphine treatment
Hannah K. Knudsen1*, Jennifer Cook2, Michelle R. Lofwall3, Sharon L. Walsh4, Jamie L. Studts5
and Jennifer R. Havens6
Abstract
Background: Opioid use disorder (OUD) is a major risk factor in the acquisition and transmission of HIV. Clinical
practice guidelines call for the integration of HIV services in OUD treatment. This mixed methods study describes
the integration of HIV services in buprenorphine treatment and examines whether HIV services vary by prescribers’
medical specialty and across practice settings.
Methods: Data were obtained via qualitative interviews with buprenorphine experts (n = 21) and mailed surveys from
US buprenorphine prescribers (n = 1174). Survey measures asked about screening for HIV risk behaviors at intake,
offering HIV education, recommending all new patients receive HIV testing, and availability of on-site HIV testing.
Prescribers’ medical specialty, practice settings, caseload demographics, and physician demographics were measured.
Multivariate models of HIV services were estimated, while accounting for the nesting of physicians within states.
Results: Qualitative interviews revealed that physicians often use injection behaviors as the primary indicator for
whether a patient should be tested for HIV. Interviews revealed that HIV-related services were often viewed as beyond
the scope of practice among general psychiatrists. Surveys indicated that prescribers screened for an average of 3.2 of
5 HIV risk behaviors (SD = 1.6) at intake. About 62.0% of prescribers delivered HIV education to patients and 53.2%
recommended HIV testing to all new patients, but only 32.3% offered on-site HIV testing. Addiction specialists and
psychiatrists screened for significantly more HIV risk behaviors than physicians in other specialties. Addiction specialists
and psychiatrists were significantly less likely than other physicians to offer on-site testing. Physicians in individual
medical practice were significantly less likely to recommend HIV testing and to offer onsite testing than physicians in
other settings.
Conclusions: Buprenorphine treatment providers have not uniformly integrated HIV-related screening, education, and
testing services for patients. Differences by medical specialty and practice setting suggest an opportunity for targeting
efforts to increase implementation.
Keywords: Buprenorphine, Opioid use disorder treatment, HIV/AIDS testing, HIV prevention
Background
Opioid use disorder (OUD) is a major risk factor in the
acquisition and transmission of HIV due to injection
and high-risk sexual behaviors [1, 2]. Despite the strong
links between OUD and HIV/AIDS, services for these
two conditions have been fragmented in the United
States, with HIV clinical care occurring in medical
settings and OUD services located in clinics that are not
embedded within mainstream medical institutions [3, 4].
This fragmentation has led to repeated calls for greater
integration, such as co-location of buprenorphine-
naloxone treatment and HIV-related services within the
same setting [5, 6].
Such integration may yield numerous health-related bene-
fits. By reducing opioid use, buprenorphine treatment re-
duces the risk of HIV acquisition through injection [2, 6–8].
Among HIV-positive patients, buprenorphine treatment re-
duces needle-sharing [9]. When buprenorphine is integrated
into HIV care clinics, patients initiating buprenorphine treat-
ment are more likely to receive antiretroviral therapy (ART)
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as well as report improvements in HIV-related medical
outcomes [10] and quality of life [11].
While buprenorphine treatment itself is an important
HIV prevention strategy, HIV testing and brief interven-
tions to decrease risky sexual behaviors represent
additional services that may yield public health benefits
[2]. As noted in models for increasing the identification
of individuals with HIV and linking them to care, such
as the National Institute on Drug Abuse’s Seek-Test-
Treat-Retain initiative [12], it is vitally important to
connect individuals, particularly those at high risk HIV,
to testing services [13, 14]. Rapid HIV testing only re-
quires a non-intrusive oral swab that yields initial results
in a brief period of time [15]. Rapid HIV tests that are
marketed directly to consumers cost less than $50 [16],
and in health care settings, per-patient costs have been
estimated at $22–$46 per patient depending on the
counseling protocol [17]. Furthermore, HIV testing is in-
cluded among the preventive services that are covered
under the Affordable Care Act [18]. Testing, subsequent
linkage to ART for individuals with HIV, and ART adher-
ence have benefits for the health of individuals, and by
reducing the individual’s viral load, prevents the further
spread of HIV [19].
In substance use disorder (SUD) treatment, the feasibil-
ity of implementing HIV testing has been demonstrated
[20]. On-site delivery of HIV testing in SUD treatment re-
sults in more individuals receiving their test results than
when individuals are referred to an off-site provider [21].
Integration of HIV testing into SUD treatment is particu-
larly important because these patients may be not receive
routine primary medical care [22]. Despite the health
benefits of early identification and linkage to care, health
services research has shown that HIV-related services
have not been extensively adopted in these settings. In
both licensed opioid treatment programs (OTPs) that pri-
marily dispense methadone and counseling-based SUD
treatment centers, the adoption of HIV testing and other
services remains limited [23–28], despite the Centers of
Disease Control and Prevention’s clinical practice guide-
lines that recommend testing in these and other health
care settings [29].
Less is known about the diffusion of HIV-related ser-
vices in buprenorphine treatment. Although some OTPs
and SUD treatment centers have adopted buprenorphine
[30], the majority of physicians delivering buprenorphine
treatment do so via prescriptions in office-based settings
outside OTPs and the specialty SUD treatment system
[31]. Research has shown that the delivery of risk reduc-
tion counseling by buprenorphine providers is feasible
[32]. However, a 2008 survey of providers participating
in the Substance Abuse and Mental Health Services
Administration’s Physician Clinical Support System-
Buprenorphine (PCSS-B) found that counseling about
sexual risk behaviors was unevenly implemented, and less
than half of these physicians conducted HIV testing [33].
The present study explores the delivery of HIV-related
services (i.e., risk assessment, education, and testing) in
buprenorphine treatment. Through qualitative interviews
with buprenorphine experts, we sought to understand the
roles of buprenorphine-prescribing physicians in the deliv-
ery of HIV prevention and testing. Then, using survey
data from a national sample of buprenorphine prescribers,
we constructed multivariate models to examine the
adoption of risk assessment practices, delivery of HIV
education, recommending that all new patients be tested
for HIV, and the availability of on-site HIV testing.
Methods
Study design
This mixed methods study integrated data from qualita-
tive interviews with buprenorphine treatment experts
and quantitative survey data collected from a large
national sample of buprenorphine prescribers. As noted
by Palinkas and colleagues [34], this type of mixed
methods approach can be best described as “qual➔-
QUAN”, in which qualitative data collection preceded
and informed the quantitative survey design. All re-
search procedures were approved by the Institutional
Review Board of the University of Kentucky.
Qualitative procedures and participants
In the qualitative phase, we recruited buprenorphine-
prescribing expert mentors within the SAMHSA-funded
Physician Clinical Support System-Buprenorphine (PCSS-
B; now the PCSS-MAT). Staff from the American Academy
of Addiction Psychiatry provided the study team with a list
of the 88 mentors in May 2013. A purposive sampling strat-
egy was used to recruit mentors from 21 unique US states
who reflected the gender, medical specialty, and practice
setting distribution of the PCSS-B mentors. This sample
size is consistent with the recommendations of Creswell
[35] and Sandelowski [36] for achieving saturation in
formative qualitative research with health care providers.
Sampled individuals (n = 33) were sent up to 4 email in-
vitations about our study. A telephone interview was
scheduled at a time convenient for the physician, and a
description of the study and the rights of research subjects
was emailed before the interview. Participants provided
verbal informed consent, and received a check for $100
for participating. Between July 2013 and January 2014, 21
interviews were conducted (response rate = 63.6%) by a
master’s level research assistant who had prior qualitative
research experience and was trained in the interviewing
protocol.
Participants were predominantly male (81.0%, n = 17)
and white (95.2%; n = 20). One participant identified as
Asian American (4.8%). In terms of medical specialty,
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57.1% (n = 12) were addiction specialists (e.g., addiction
medicine, addiction psychiatry), 23.8% (n = 5) were
general psychiatrists, and 19.1% (n = 4) worked in other
specialties (e.g., internal medicine, family medicine, ob-
stetrics/gynecology). About 33.3% (n = 7) were affiliated
with an academic medical center, 9.5% (n = 2) were
affiliated with a Veterans Administration medical center,
and 57.1% (n = 12) were not affiliated with either type of
medical center.
While interviews largely focused on the practices consti-
tuting high-quality buprenorphine treatment, one section
included questions specific to HIV services. Physicians
were asked, “What is the role of buprenorphine-
prescribing physicians in the delivery of HIV prevention,
testing, and treatment?” All interviews were digitally
recorded and professionally transcribed.
A qualitative description approach was employed to
analyze the data [37], which is well-suited when describ-
ing participants’ perceptions and developing quantitative
measures [38]. The lead author (HKK) initially used an
inductive approach to identify major themes and then
assigned descriptive codes to segments of the transcripts.
These descriptive codes were collated into a codebook.
A second coder (JC) then read the transcripts and
employed the codebook to independently code each
transcript. An iterative process was used to reach
consensus on the selection of quoted passages from the
coded transcripts of the themes represented in the data.
Quantitative survey procedures
Quantitative survey data were collected from a national
sample of civilian physicians who prescribe buprenorphine
for the treatment of OUD. Civilian physicians were identi-
fied the Drug Enforcement Agency’s May 2014 Controlled
Substances Act Registrants database (n = 24,506) Waivered
physicians were randomly sampled within states to achieve
a national sample reflecting the geographic distribution of
waivered physicians across the US.
Telephone screening was used to determine study eli-
gibility. The primary criterion for eligibility was current
treatment of at least one patient with buprenorphine for
OUD at the time of screening. Up to 10 attempts were
made to gather the screening information, after which
another randomly selected physician from his or her
state replaced that physician.
The survey protocol was informed by Dillman’s [39]
tailored design method and consisted of an advance
notification letter, express-mailing (i.e., FedEx® or US
Priority Mail) the survey packet, sending a postcard
reminder, and calling physicians after 6 weeks of non-
response and re-sending the survey. Participating physi-
cians received an honorarium of $100 by mail. Surveys
were mailed to 3553 physicians identified as eligible dur-
ing screening, and 1174 participated in the survey
(33.0% response rate) between July 2014 and January
2017. Survey data were entered into the REDCap (Research
Electronic Data Capture) system [40], which is hosted by
the University of Kentucky’s Center on Clinical and
Translational Science. Participant characteristics appear
in Table 1.
Survey measures
Survey measures asked physicians about HIV risk assess-
ment, education, and testing. First, physicians indicated
(1 = yes, 0 = no) whether all new patients were asked
about: (1) frequency of injection drug use; (2) sharing of
syringes, (3) sharing of non-syringe drug paraphernalia,
(4) number of sexual partners, and (5) frequency of un-
protected sexual intercourse. The rationale for including
these practices is that common HIV risk assessment
instruments, such as the Risk Behavior Assessment [41]
and the HIV Risk Questionnaire [42], focus on these
behaviors. These items were summed into an index of
HIV risk assessment practices that ranged from 0 to 5.
A dichotomous measure asked physicians whether they
delivered HIV education to their patients (1 = yes,
0 = no). Additional descriptive items asked about the ex-
tent (0 = no extent, 5 = very great extent) to which HIV
educational efforts emphasized how HIV is transmitted,
the importance of not sharing syringes and other drug
paraphernalia, development of safer sex practices, re-
hearsing correct condom use, and communicating with
partners about safer sex practices; physicians who re-
ported not delivering HIV education were coded as “0”
on these descriptive items. These measures were adapted
from prior studies of HIV services in specialty SUD
treatment [23, 43]. Dichotomous items asked physicians
whether they recommended HIV testing to all new pa-
tients (1 = yes, 0 = no) and whether HIV testing was
conducted on-site at their office (1 = yes, 0 = no).
Medical specialty and practice setting were two key in-
dependent variables of interest based on our qualitative
findings. The survey asked physicians about their spe-
cialty or area of medical practice using an open-ended
format. Trained research staff then coded these re-
sponses into three mutually exclusive groups: addiction
specialists (addiction medicine or addiction psychiatry),
psychiatrists (with no mention of addiction), and other
prescribers from all other specialties.
Physicians were asked six dichotomous items whether
they prescribed buprenorphine in individual medical
practice, group medical practice, a Veterans Administra-
tion medical center (VAMC), a hospital (non-VAMC),
an opioid treatment program (OTP, i.e., methadone pro-
gram that also offers buprenorphine treatment), and/or
a non-OTP SUD treatment program. Prescribers could
indicate more than one setting, so these variables were
treated as separate dichotomous variables.
Knudsen et al. Substance Abuse Treatment, Prevention, and Policy  (2017) 12:37 Page 3 of 13
To measure caseload characteristics, physicians indi-
cated the percentage of their patients in the past year
who had heroin use disorder (but not prescription
opioid use disorder), the percentage who had both
prescription opioid and heroin use disorder, and the
percentage with prescription opioid use disorder (but
not heroin use disorder). Because these three vari-
ables sum to 100% and are interrelated (an increase
of one necessitates a decrease in the others), the
multivariate models excluded the percentage of
patients with co-occurring prescription opioid and
heroin use disorder.
Physician characteristics including age in years, gender
(1 = female, 0 = male), and race/ethnicity (with white as
the reference category, Asian, and all others in the
multivariate models) were measured. Information re-
garding whether the physician was waivered to treat up
to 30 (=0) or 100 patients (=1) was extracted from the
DEA’s May 2014 CSA database.
Finally, two state-level variables were incorporated into
the model. Because our survey was fielded during the
era of health reform, we incorporated a measure of
state-level approaches to implementing the Medicaid
expansion and state-based health insurance exchanges
under the Affordable Care Act (ACA) of 2010. This
federal legislation, which was implemented during the
presidency of Barack Obama, sought to reduce the number
of uninsured Americans and improve population health.
The ACA required all Americans to obtain health insur-
ance (called the “individual mandate”) and contained provi-
sions to support access to health insurance, such as
expanding Medicaid to include adults with incomes of less
than 138% of the federal poverty line [44] and combina-
tions of tax credits and subsidies for individuals purchasing
coverage via state-based or federal insurance exchanges
[45]. Our measure of ACA implementation represents a
three-category typology based on information published by
the Henry J. Kaiser Family Foundation [46, 47]. We
Table 1 Characteristics of buprenorphine-prescribing physicians and their practices reported as mean (standard deviation) or
percentage (count)
Mean (SD) or % (N) 95% CI N
Medical Specialty 1149
Addiction specialty (medicine or psychiatry) 21.6% (248) 19.2–24.0
Psychiatry (i.e., adult and/or child psychiatry with no mention of addiction) 27.2% (312) 24.6–29.7
All others (e.g., family medicine, internal medicine, primary care, emergency medicine) 51.3% (589) 48.4–54.2
Practice Settings
Individual medical practice 50.8% (587) 47.9–53.7 1155
Group medical practice 35.2% (406) 32.4–37.9 1155
Veterans Administration medical center (VAMC) 4.6% (53) 3.4–5.8 1155
Hospital (non-VAMC) 13.2% (152) 11.2–15.1 1155
Opioid treatment program (OTP dispensing methadone) 6.2% (71) 4.8–7.5 1155
Non-OTP substance use disorder treatment program 13.9% (161) 11.9–15.9 1155
Caseload Characteristics
Percentage of past-year patients with heroin use disorder (but not prescription opioids) 23.5 (22.4) 22.2–24.8 1135
Percentage of past-year patients with prescription opioid use disorder (but not heroin) 54.5 (27.3) 52.9–56.1 1134
Percentage of past-year patients with co-occurring heroin and prescription opioid use disorder 22.8 (19.9) 21.6–23.9 1133
Physician Characteristics
Age 55.5 (11.4) 54.8–56.1 1160
Female 22.9% (267) 20.5–25.3 1165
Race and ethnicity 1148
White 76.5% (878) 74.0–78.9
Asian American 12.5% (144) 10.6–14.5
African American/Black 4.7% (54) 3.5–5.9
Hispanic/Latino 4.4% (50) 3.2–5.5
All others 1.9% (22) 1.1–2.7
Waivered to treat up to 100 patients 57.8% (678) 54.9–60.6 1174
Note. Percentages may not sum to 100% due to rounding
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categorized ACA-supportive states as those that expanded
Medicaid and implemented a state-based health insurance
exchange (15 states and the District of Columbia).
ACA-hybrid states chose to either expand Medicaid
or establish a state-based exchange, but did not im-
plement both policies (11 states); 10 of these states
implemented the Medicaid expansion. ACA-resistant
states included states that chose to not expand
Medicaid and did not establish a state-based exchange
(24 states). A second state-level measure drew upon
data on the number of individuals living with diagnosed
HIV infection per 100,000 state residents in 2014 [48].
States below the mean (i.e., 299 individuals living with
HIV/AIDS per 100,000 residents) were categorized as low
prevalence states (=1; 32 states) and those at or above the
mean were categorized as high prevalence states (=0; 18
states and District of Columbia).
Quantitative data management and analysis
Descriptive statistics were calculated for all study vari-
ables. To avoid the bias that results from complete case
analysis [49], multiple imputation by chained equations
was implemented using “mi impute chained” in Stata
13.1 as a method to address missing survey data [50].
Rates of missing data ranged from 0.8% for gender to
4.0% for the index of HIV risk assessment practices. Our
specification of “mi impute chained” included the index
of HIV risk assessment, the dichotomous measure of de-
livering HIV education, the measure of recommending
HIV testing to new patients, availability of on-site HIV
testing, and all of the independent variables, with each
variable imputed based on the appropriate link function
(e.g., logistic regression if dichotomous, Poisson regres-
sion if a count, etc.). Thirty datasets were generated
from the imputation procedure, and these datasets were
used for the estimation of mixed effects regression
models for each of the dependent variables of interest
(i.e., “melogit” for dichotomous dependent variables and
“mepoisson” for the index of HIV risk assessment). Each
of these models accounted for the nesting of physicians
within states and incorporated the two state-level mea-
sures as fixed effects.
Results
Qualitative findings regarding buprenorphine prescribers
as significant providers of HIV-related services
Almost all of the physicians in the qualitative sample
indicated that buprenorphine prescribers should have a
significant role in provision of HIV (and hepatitis C;
HCV) services. One of the primary ways that buprenor-
phine prescribers talked about involvement was in
relation to HIV testing. Some physicians indicated their
support for testing all patients regardless of specific risk
factors. For example, one physician stated:
“I don’t think it’s compulsory, but I think that is a
standard of care. I mean, I think you need to do some
lab work when you bring patients in. You know HIV
and HCV. Absolutely I think it’s below standard of care
if you’re not assessing any patient that is a substance
abuser, particularly if they’re intravenous. But I do it on
all of them.” (Male, Addiction Specialist)
Others also discussed the importance of assessing HIV
risk and delivering counseling related to risky behaviors.
Many physicians noted the importance of determining
whether or not the patient injected drugs. Others indi-
cated the need to assess for other risk factors, as noted by
the following physician: “Obviously every Suboxone®
doctor should be asking about HIV risk factors, not just,
you know, IV drug use but also unprotected sex” (Male,
Addiction Specialist). Some also discussed the importance
of providing risk reduction counseling to their patients,
like the following physician who discussed risk reduction
counseling for individuals who tested negative for HIV:
“And then the role would be if it’s negative to try to
reinforce the fact you’re negative; please don’t engage
in risky behavior, please don’t inject any longer. I
might say to a patient, you know if you do relapse, if
that should happen, if you could just use it
intranasally and not inject, that would be much better
than injecting.” (Male, General Medicine)
These physicians acknowledged the importance of
addressing risk factors and providing counseling services
to reduce the risk of their patients contracting HIV.
Physicians also described the significance of their role
in providing services for HIV-positive patients. Many
physicians highlighted the importance of referring HIV-
positive patients to HIV care, such as the following
physician who stated, “and if they’re positive, well then
they have to be referred for appropriate treatment,
which some HIV waivered physicians can do” (Male,
General Medicine). Thus, these physicians highlight the
importance of ensuring their patients are referred to an
HIV specialist to receive the treatment they need to
meet all of their medical needs.
Qualitative findings about focusing HIV services only on
“high risk” patients
Although almost all physicians discussed the importance
of HIV services for patients who use drugs, some physi-
cians only delivered such services to individuals who
reported injection drug use. For example, one physician
stated: “But I would say that when you take your initial
history from the opioid addicted patient sitting there,
that certainly if somebody has been an injection drug
user, that that would be something that, you know, they
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should just have a preliminary HIV and hepatitis C
screening to see if they’re negative or not” (Male, Addiction
Specialist). This physician highlighted how he would defin-
itely recommend an HIV test for those who injected drugs
but did not indicate whether HIV testing would be import-
ant for all patients. Another doctor was more specific,
indicating that he only recommended testing for patients
who have injected drugs:
“Oh, I only test people for HIV and hepatitis if they’re
IV drug users. And the majority of most of my
patients are prescription drug users who don’t, you
know, don’t use needles. So I do test everybody who’s
an IV drug user. I may ask them if they’ve shared or
reused the needle and, if they’ve never done that, I’m
less likely (Male, Addiction Specialist).”
These data suggested that some buprenorphine physi-
cians evaluated HIV risk solely based on injection use.
In some cases, the physician acknowledged that not
testing each patient did not align with recommendations
of the CDC; as one physician noted, “Well I guess I
think that the CDC, I think, has recommended that like
everyone has an HIV test… Although I don’t really
follow that rule but I think that that is something they
did recommend” (Male, General Medicine).
A minority of physicians indicated they did not per-
ceive their patient population to be at high risk for HIV,
and thus, did not deliver any HIV testing or prevention
services. For example, one physician had difficulty
addressing the question about HIV service delivery due
to his perception of low injection drug use among his
patients: “That’s a kind of more of a philosophical ques-
tion. I don’t deal very much with positive HIV folk; I
haven’t seen too many… Because first they don’t, well in
[this state] there’s much less IV use of opiates” (Male,
Psychiatrist). The physician’s focus on his entire state
rather than specific individuals within his practice led
him to conclude that HIV testing and prevention were
not needed despite CDC recommendations regarding
universal testing. Similarly, another physician cited a low
rate of needle-sharing in his population as a reason not
to deliver HIV services: “Most people these days that I
treat are negative…Because of needle exchanges or just
being able to go to the drug store and buy sterile needles”
(Male, General Medicine).
Qualitative findings on HIV services by physician specialty
and practice setting
Another major theme that emerged was how the provision
of HIV risk assessment, education, and testing to patients
varied by the medical specialty and practice setting of the
physician. Many physicians indicated that specialties like
family medicine and primary care were better suited to
deliver HIV-related services than physicians who do not
provide primary care services, such as psychiatrists. One
physician discussed how he believed many non-primary
care specialties avoid HIV risk assessment and HIV testing
due to the detailed medical history and laboratory work
involved: “Unfortunately I don’t think it happens very
regularly much because, and not that one needs to be a
primary care, in general medicine, family practice, to go
into this, but I think a part of every evaluation needs to in-
clude a complete history, physical exam, and appropriate
laboratory screening” (Male, Addiction Specialist). Other
physicians indicated they were not typically involved in
HIV service delivery because they assumed primary care
doctors filled this role. One psychiatrist perceived that she
should focus only on how buprenorphine may interact
with other drugs each patient may take, by stating, “You
know, I’m a psychiatrist. I think a primary care doctor is
more involved, but certainly psychiatrists, you know, we
do need to know drug/drug interactions and that sort of
thing” (Female, Psychiatrist). Another physician described
how HIV testing was the responsibility of primary care
providers, as illustrated in the following interaction
between the interviewer (I) and respondent (R):
“I: What would you say is the role of buprenorphine
prescribing physicians in the delivery of HIV
prevention, testing and treatment?
R: None.
I: Okay. Why?
R: Yeah, we do some, we do some but, well okay,
that’s not a true statement. So for the ones who were
in, you know like, first line settings where they are
methadone clinic type settings. You know where
you’re taking people who are untreated and then
obviously HIV testing is important in that setting.
Okay. For the docs who have the more established
patients and the higher functioning patients, … a lot
of those patients have the, have, already have primary
care, I think that’s the primary care’s responsibility.”
(Female, Addiction Specialist)
National survey results regarding availability of HIV-
related services
Table 2 presents descriptive data regarding the availabil-
ity of HIV-related services in buprenorphine treatment.
Nearly all respondents indicated that they asked all new
patients about injection drug use, and most physicians
asked about syringe sharing. Fewer physicians asked all
new patients about sharing other types of paraphernalia,
the number of sexual partners, and frequency of unpro-
tected intercourse. The majority of physicians reported
that they delivered HIV education to patients. The
means for the specific elements of HIV education were
at or below the midpoint for these scales. The means for
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education focused on sexual risks were even lower and
about half the magnitude of the means for education
focused on drug-related risks. About half of the sample
recommended HIV testing to all new patients, yet only
about one-third of physicians offered on-site HIV testing.
Multivariate models of HIV-related services
Table 3 presents the results from four mixed effects
regression models of the adoption of risk assessment prac-
tices, delivery of HIV education, recommending that all
new patients be tested for HIV, and the availability of on-
site HIV testing. Differences by medical specialty varied
depending on the type of HIV-related service. Addiction
specialists and psychiatrists both reported assessing a
greater number of the five types of HIV risk behaviors
than physicians in other specialties. Addiction specialists
and psychiatrists were significantly more likely to deliver
HIV education to patients. However, these two types of
specialists were significantly less likely than physicians in
other specialties to offer on-site HIV testing. Furthermore,
psychiatrists were significantly less likely to recommend
HIV testing to all new patients, relative to physicians from
non-addiction/non-psychiatry specialties.
Practice settings were associated with the odds that phy-
sicians delivered HIV education, recommended testing,
and offered on-site HIV testing. Physicians delivering
buprenorphine in individual medical practice were less
likely to recommend HIV testing and less likely to offer
on-site HIV testing, relative to physicians in other settings.
However, physicians working in VAMCs, relative to those
not delivering buprenorphine in VAMCs, were signifi-
cantly more likely to deliver HIV education, recommend
all new patients be tested for HIV, and to offer on-site
HIV testing. Delivering buprenorphine in a non-VAMC
hospital was positively correlated with the odds of deliver-
ing HIV education and offering on-site HIV testing. The
only HIV service associated with delivering buprenorphine
in an OTP was HIV education, and this association was
positive in direction. Physicians practicing in non-OTP
specialty SUD programs were significantly less likely than
those in other settings to report on-site HIV testing.
Delivering buprenorphine in a group medical practice was
not associated with any of the four HIV services. Notably,
none of the practice settings were correlated with the
index of risk assessment intake practices.
Caseload characteristics were correlated with some
HIV-related services. The percentage of OUD patients in
treatment because of prescription opioids (but not
heroin) was negatively associated with three of the four
HIV-related services. Specifically, physicians who treated
a higher percentage of patients for prescription opioids
reported using significantly fewer HIV risk assessment
Table 2 Characteristics of HIV-related services in buprenorphine treatment reported as mean (standard deviation) or percentage (count)
Mean (SD) or % (N) 95% CI N
Intake practicesa
All new patients are asked about frequency of injection drug use 92.4% (1055) 90.8–93.9 1142
All new patients are asked about sharing of syringes 82.9% (944) 80.7–85.1 1139
All new patients are asked about sharing of non-syringe drug paraphernalia
(e.g., straws, cottons, cookers)
53.2% (604) 50.3–56.1 1136
All new patients are asked about number of sexual partners 48.0% (548) 45.1–50.9 1141
All new patients are asked about frequency of unprotected sexual intercourse 48.5% (554) 45.6–51.4 1142
Count of intake practices 3.2 (1.6) 3.1–3.3 1127
HIV education
Physician delivers HIV/AIDS education to his/her patientsa 62.0% (709) 59.2–64.8 1144
Patient education emphasis on how HIV/AIDS is transmittedb 2.0 (1.9) 1.9–2.2 1136
Patient education emphasis on the importance of not sharing syringesb 2.5 (2.2) 2.4–2.6 1137
Patient education emphasis on the importance of not sharing other drug paraphernaliab 2.1 (2.1) 1.9–2.2 1136
Patient education emphasis on development of safer sex practicesb 2.1 (2.0) 2.0–2.2 1132
Patient education emphasis on skill rehearsal of correct condom useb 0.7 (1.4) 0.7–0.8 1335
Patient education emphasis on practicing partner communication and negotiation skills
about safer sex practicesb
1.0 (1.5) 1.0–1.1 1133
Mean scale of patient education 1.7 (1.6) 1.7–1.8 1127
HIV testinga
Recommend that all new patients be tested for HIV/AIDS 53.2% (610) 50.3–56.1 1146
On-site HIV testing (rapid or non-rapid) 32.3% (370) 29.5–35.0 1147
Notes. aDichotomous measures (1 = yes, 0 = no). bLikert responses (0 = no extent to 5 = very great extent)
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practices and were significantly less likely to deliver HIV
education. Furthermore, physicians with larger caseloads
of prescription opioid patients were significantly less
likely to recommend HIV testing to all new patients.
However, the percentage of patients who were in treat-
ment because of heroin was not associated with any of
the four HIV-related services.
Physicians’ characteristics were correlated with delivery
of some HIV-related services. Age was positively corre-
lated with the number of risk assessment practices dur-
ing intake, but negatively correlated with the likelihood
that the physician offered on-site HIV testing. Female
physicians were more likely than male physicians to rec-
ommend HIV testing to all new patients. There were no
differences by race/ethnicity. The only difference by the
type of buprenorphine waiver was that physicians with
the 100-patient waiver had adopted fewer of the HIV
risk assessment practices than physicians with the 30-
patient waiver.
Finally, there was little evidence that the two state char-
acteristics were associated with HIV services. The only sig-
nificant difference was that physicians in ACA-supportive
states were more likely than those in ACA-resistant states
to recommend HIV testing to all new patients. The state-
level prevalence of people living with HIV/AIDS was not
associated with any of the HIV-related services.
Discussion
The elevated risk of HIV acquisition and transmission for
individuals with OUD suggests the need for integrating
HIV services within buprenorphine treatment settings.
The CDC’s guidelines recommend the integration of HIV
testing in all medical settings [29]. With the advent of
rapid HIV tests that do not require phlebotomy facilities,
adoption and implementation should be feasible in a
range of settings. However, this mixed methods study
found that the availability of specific HIV-related services
was quite variable in buprenorphine treatment. Availabil-
ity was correlated with medical specialty, practice setting,
and the percentage of patients in treatment because of
prescription opioids.
Physicians’ focus on assessing HIV risk via injection-
related risk behaviors was borne out in both our qualitative
data and our national survey. In the qualitative interviews,
buprenorphine experts often described the need to ask
patients about injection behaviors. Our survey data was
consistent with this finding, as the vast majority of bupre-
norphine prescribers reported asking new patients about
injection and syringe sharing. Yet, there was evidence in
both the qualitative interviews and survey data that some
physicians assumed that individuals seeking buprenorphine
treatment because of prescription opioids were at limited
risk of acquiring HIV. In the multivariate models, physi-
cians treating greater percentages of such patients reported
using fewer risk assessment practices, were less likely to
deliver HIV education, and were less likely to recommend
HIV testing. Epidemiological studies have shown that
many individuals who misuse prescription opioids do inject
these substances [51–53], so perceptions of limited HIV
risk among those who use prescription opioids may result
in missed opportunities for intervention. Focusing on
individuals who inject opioids may be targeting those at
highest risk, but individuals who do not inject still face
risks if they engage in risky sexual behaviors.
Both the qualitative interviews and survey data revealed
considerably less emphasis on sexual risk behaviors in
physicians’ assessment of HIV risk. Such findings are not
altogether unexpected, given that medical providers across
specialties are often reticent to discuss sexual behaviors
[54]. Even in HIV care clinics when HIV-positive patients
disclose high-risk sexual behaviors, providers are often
reluctant to deliver risk reduction counseling to patients
[55, 56]. Nonetheless, limited implementation of assess-
ment of risky sexual behaviors and sexual risk reduction
counseling represents a missed opportunity. Epidemio-
logical research has shown that sexual transmission of
HIV is common among individuals who use drugs,
whether they inject or not [57], underscoring the need to
follow CDC recommendations for HIV testing. Reduc-
tions of risky sexual behaviors may reduce the incidence
of new cases of HIV [58], and counseling by medical pro-
viders is one intervention that may target these behaviors.
Models for improving the identification of individuals
with HIV and linking them to care, such as Seek-Test-
Treat-Retain [12], begin with efforts to encourage
individuals at high-risk of HIV to be tested [13, 14]. Our
survey data showed that only about half of buprenor-
phine physicians recommended HIV testing to all new
patients, and only one-third offered on-site HIV testing.
This uneven implementation of HIV testing was consist-
ent with an earlier survey conducted by Edelman et al.
[33]. Both our qualitative and quantitative findings
suggest that many buprenorphine prescribers see HIV
testing as outside their scope of practice because of their
medical specialties and delivery settings. Buprenorphine
experts drew boundaries between psychiatry and general
medical care, and our survey results demonstrated sig-
nificant differences in adoption of HIV testing between
psychiatrists and those in non-addiction/non-psychiatry
specialties. Furthermore, addiction specialists were less
likely to have adopted on-site HIV testing than physi-
cians from other medical specialties. The significantly
lower adoption of testing by those in solo practice also
corroborated our qualitative findings. Given that order-
ing laboratory tests are within the scope of practice for
all medical specialties, it is somewhat surprising that
some physicians viewed ordering an HIV test as outside
their own scope of practice.
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It is important to note that limited implementation of
HIV testing is not unique to physicians offering buprenor-
phine treatment. A survey of primary care physicians in
the state of New York found only about 40% of physicians
routinely implement HIV testing [59]. Limited adoption of
HIV testing in specialty SUD treatment settings has been
repeatedly documented [23–28, 60]. Nonetheless, the ele-
vated prevalence of HIV among individuals who use drugs
suggests that lack of adoption of HIV testing may reduce
the likelihood that patients learn their status, which is a
critically important first step in linking individuals who
test positive to HIV care. Thus, we recommend that the
buprenorphine waiver training courses review these
recommended HIV services along with models of their
effective adoption in order to ensure that new providers
are being adequately educated and trained.
There are a number of limitations inherent in the study
design. Both the qualitative and quantitative data collec-
tion were cross-sectional in their design, so causal claims
and inferences cannot be made based on these findings.
The measures of HIV-related services have not, to our
knowledge, ever been validated against objective mea-
sures, such as health records or patients’ reports of service
receipt. We only considered a limited range of independ-
ent variables. Other variables, such as HIV stigma, may
serve as barriers to the adoption of HIV-related services;
future research should consider this possibility. In
addition, the qualitative phase focused on individuals who
served as mentors to others interesting in implementing
buprenorphine treatment; they likely constitute a unique
subset of providers. Their perspectives on the delivery of
HIV services may differ from individuals who are less
experienced or who have not committed to mentoring
others. However, consistency between our qualitative re-
sults and the statistical models do suggest that the themes
identified may have some resonance with the broader field
of buprenorphine prescribers.
An additional limitation is that, at the time of the study,
only physicians were permitted to prescribe buprenor-
phine and for most of the study period, physicians were
limited to no more than 100 concurrent patients. Recent
policy changes [61] will soon allow nurse practitioners
and physician assistants to prescribe buprenorphine,
which may allow buprenorphine to diffuse to additional
settings. The current study on HIV-related services cannot
speak to the types of HIV services that may be available
once nurse practitioners and physician assistants are able
to deliver buprenorphine treatment. These professions
typically are oriented toward preventive services, of which
HIV testing is one element. Adding information about
HIV education and testing to the new training require-
ments for this potentially large group of future providers
may be an important consideration. In addition, physi-
cians can now apply to treat up to 250 patients. Given that
we found that higher volume providers (i.e., those with
the 100-patient waiver) were not more likely to offer HIV-
related services, it may suggest that extra efforts, such as
continuing medical education, may be needed to prompt
the adoption of such services by high volume buprenor-
phine providers with large caseloads of individuals with
opioid use disorder.
A substantial limitation of the survey data was a limited
response rate. Large-scale surveys of physicians often face
this challenge [62, 63]. We are unable to estimate the im-
pact of non-response, although we will be able to compare
respondents and non-respondents once we complete our
planned 12-month follow-up survey. Although higher
response rates are often assumed to be superior to lower
response rates, the broader literature on survey design has
revealed increases in response rates are not as influential
as many assume. Research has shown that response rates
have minimal impact on point estimates [64] as well as
correlations between variables [65]. Nonetheless, the
extent to which these findings generalize to those who did
not participate in the survey is unknown.
Conclusion
This mixed methods study revealed ongoing challenges to
the full integration of HIV-related services into the bupre-
norphine treatment system in the US. The limited adop-
tion of HIV prevention and HIV testing suggests that
future research should focus on identifying barriers to
providing HIV testing as well as testing implementation
strategies to expand the delivery of these HIV-related
services by buprenorphine providers. Implementation
strategies often combine a variety of efforts, such as stra-
tegic planning, training, identification of funding, and
restructuring work processes, to increase the use of a
given intervention [66]. The growing field of implementa-
tion science [67–70] can be drawn upon to identify poten-
tial combinations of strategies that may prove fruitful in
increasing the integration of HIV services in buprenor-
phine treatment. Additional dissemination of the CDC
guidelines may raise awareness about the importance of
HIV testing and risk reduction counseling [71]. Training
may be important to reduce provider discomfort in offer-
ing HIV testing [72], to identify procedures for follow-up
when patients test positive for HIV [73], and to inform
providers about state regulations related to testing [20].
Implementation efforts in large health systems, such as
the Veterans Administration, have shown that rates of
HIV testing increased after system change initiatives that
included social marketing of HIV testing to providers,
training for clinic staff, clinical reminders within the elec-
tronic health record, and publicity campaigns within clinic
waiting rooms [74]. By documenting the limited adoption
of HIV testing among addiction specialists and psychia-
trists as well as those in solo practice, these findings
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suggest that buprenorphine providers may be important
groups to target in future implementation research.
Buprenorphine providers may serve an even more
significant role in reducing the spread of HIV if
greater implementation of HIV-related services can be
achieved.
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